Allena Pharmaceuticals, Inc.
ALNAQ · OTC
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.01 | 0.05 |
| FCF Yield | -23.71% | -96.96% | -28.24% | -16.86% |
| EV / EBITDA | -1.59 | -1.50 | 2.98 | -3.18 |
| Quality | ||||
| ROIC | -108.59% | -69.61% | 28.08% | -34.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.54 | 1.70 | -2.35 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 77.26% | -56.20% | -10.00% | -2.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | 0.31 | -5.51 | 2.43 |
| Interest Coverage | -70.48 | -46.44 | -22.93 | -49.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |